mfs: a new endpoint for nonmetastatic crpc
Published 6 years ago • 380 plays • Length 5:50Download video MP4
Download video MP3
Similar videos
-
5:55
the future of treatment for nonmetastatic crpc
-
3:03
nonmetastatic crpc: mfs and ar-targeted agents
-
6:50
ep. 6: identifying nonmetastatic crpc
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
6:51
understanding nonmetastatic crpc: an overview
-
1:52:45
aua guidelines on advanced/metastatic/castration resistant prostate cancer webcast (2021)
-
6:18
how to beat castration-resistant prostate cancer today
-
2:06:21
pcl #62 the current & future landscape - metastatic castrate resistant prostate cancer-oliver sartor
-
1:10
dr. gomella on the fda approval of apalutamide for nonmetastatic crpc
-
21:25
an update on the prosper trial: focusing on nonmetastatic crpc
-
0:57
dr. dorff on choosing between therapies in nonmetastatic crpc
-
1:19
nonmetastatic crpc: meeting an unmet need
-
5:04
fda approved agents for non-metastatic crpc
-
1:45
dr. choudhury on antiandrogen treatment selection in nonmetastatic crpc
-
5:52
clinical trials in non-metastatic crpc
-
0:44
dr. wise on the fda approval of apalutamide in non-metastatic crpc
-
3:06
enzalutamide in the context of nonmetastatic crpc
-
4:32
nonmetastatic crpc: the changing landscape of treatment
-
4:36
nonmetastatic crpc: initial therapeutic approach
-
5:01
fda d.i.s.c.o.: a new drug approval for non-metastatic castration-resistant prostate cancer
-
0:51
dr. gomella on the fda approval of enzalutamide in nonmetastatic crpc